# Medtronic share price today (Medtronic plc, MDT)

> Medtronic plc's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. MDT · Healthcare · Medical Devices · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/mdt

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: $105.04 (+13.9% in a year)
- P/E: 25.9× (lower than 54% of the last 4.5 years)
- Revenue (Jul 2026): $9.8 B (+13.7% on a year ago)
- Profit (Jul 2026): $1.5 B (+41.3% on a year ago)
- Operating margin: 19.3% (+0.6 points on a year ago)
- ROE: 10%, FY26
- ROIC: 8.6%, against a 6.4% cost of capital: +2.2 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Medtronic share price today? Medtronic plc's share price was $105.04 at the close on 4 November 2026. It has been stalling near its high for 5 weeks. That is 19.1% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 15 weeks in a row. In the last 52 weeks it traded between $74 and $105, and at that close it sat 99% of the way up from that low. Over the last 10 years the share price moved +19% while the S&P 500 moved +261%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Medtronic pay? Medtronic plc paid $2.85 per share over the last four reported quarters. The most recent declaration was $0.72 for Jul 2026. At today's price of $105.04 that is a yield of 2.71%, based on dividends already paid, not a forecast. ## Which stock lists is Medtronic on? Medtronic is on one of our US lists: S&P 500 companies. [S&P 500 companies](https://www.sectoralpha.in/sp-500-stocks)

## Is Medtronic profitable? Medtronic plc earned $1.5 B of net profit in the Jul 2026 quarter, +41.3% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was $4.8 B. Over 4 years profit has grown −1.2% a year on average. That is 15.1% of the quarter's revenue. The same quarter a year earlier earned $1.0 B. For the full year, FY26 profit was $4.8 B (+3.0% on the year before). Why profit moved: revenue changed +13.7% on a year earlier and the margin moved +0.6 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +13.9% and revenue +9.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Medtronic make, and is it growing? Medtronic plc reported $9.8 B of revenue in the Jul 2026 quarter, +13.7% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 3.5% a year on average. The last full year, FY26, came in at $36.4 B. The last four reported quarters add to $37.5 B. FY26 revenue was $36.4 B, +8.4% on the year before. Recent pace: the last four quarters grew +9.7% on average, against 3.5% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +9.8%, against +7.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +12.3%, against +15.4% a year (rolling over). ## How much of every $100 of sales does Medtronic keep? Medtronic plc's operating margin was 19.3% in the Jul 2026 quarter, 0.6 percentage points higher than the same quarter a year ago. Across 5 years it has been between 17.8% and 21.6%. The latest quarter is within that range. Why the margin moved: operating margin changed +0.6 percentage points on the year while gross margin changed −0.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Medtronic's profit turning into cash? Over the last 3 years, 161% of Medtronic plc's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in $7.3 B of operating cash against $4.8 B of profit. After $1.9 B of spending on assets, $5.4 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Medtronic's cash go? Medtronic plc does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $5.3 B on assets over the last 3 years. Averaged over those years that is 4.9% of FY26 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $5.3 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Medtronic's P/E ratio, and how does it compare with its own history? Medtronic plc's P/E is 25.9×, in the middle of its own history: higher than 46% of past readings. Its usual P/E (the middle reading) is 26.2×, over 4.5 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +3.3% while the price moved +13.9%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +13.1% a year; about +9.9% a year came from earnings growth and about +3.2 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Medtronic business getting better or worse? Medtronic plc's business is giving mixed signals. Growth has been steadily positive, but ROCE at 9.5% is below the 15% level needed to call it steady growth. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Medtronic earn on its capital? Medtronic plc earned a ROE of 10% in FY26. That is up from a low of 7% in FY23. Its return on capital used (ROIC) is 2.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 13.2% net margin and 0.39× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 13.2% net margin × 0.39× asset turnover × 1.86× leverage (assets divided by equity) ≈ 9.6% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 8.6% − 6.4% = +2.2 percentage points. The 6.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Medtronic have too much debt? Medtronic plc has total debt of $28.2 B against shareholder equity of $50.9 B as of Jul 2026, so its debt is 0.55× its equity. Year by year, that ratio went from 0.47 in FY22 to 0.58 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Medtronic shareholding pattern? 11.4% of Medtronic plc's tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 4.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Medtronic from balance-sheet trouble? For Medtronic plc, the Z-score is 2.98. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.98 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Medtronic rank in its industry? 55.1 out of 100, rank 9 of 30 in Medical Devices, with 85% of the evidence available. Medtronic plc scores 55.1 out of 100 against the 30 companies it is compared with in Medical Devices, ranking 9. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 19.1 + 14.3 + 9.3 + 12.4 = 55.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Medtronic compared with? Medtronic ranks 9 of 30 Medical Devices companies on the 4-Factor Sector Score, with 55.1 out of 100. 1. [DexCom, Inc.](https://www.sectoralpha.in/us/stocks/dxcm) DXCM · turning · Most evidence points up · 81% evidence 73.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 15.5% · Profit 74.8% · Operating margin change 5.9 points · 83% evidence Capital efficiency 20.9/25 · ROCE 27.8% · Operating margin 24.3% · 76% evidence Valuation 13.6/20 · P/E 26× · PEG 0.66 · 65% evidence Relative strength 11.0/20 · Lead over its industry 1.7% · Lead over S&P 500 13.9% · 1 year 60.9% · 100% evidence · 11 of 12 weeks ahead Exact sum: 28 + 20.9 + 13.6 + 11 = 73.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Globus Medical, Inc.](https://www.sectoralpha.in/us/stocks/gmed) GMED · turning · Most evidence points up · 81% evidence 65.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 19.8% · Profit 50.1% · Operating margin change 7.5 points · 83% evidence Capital efficiency 17.5/25 · ROCE 14.6% · Operating margin 24.8% · 76% evidence Valuation 14.9/20 · P/E 20× · PEG 0.4 · 65% evidence Relative strength 5.2/20 · Lead over its industry -13.9% · Lead over S&P 500 -3.6% · 1 year 3.8% · 100% evidence · 1 of 12 weeks ahead Exact sum: 28 + 17.5 + 14.9 + 5.2 = 65.6 · What this means: Earnings are strong; relative strength in its sector is -13.9% and the one-year return is 3.8%. 3. [Boston Scientific Corporation](https://www.sectoralpha.in/us/stocks/bsx) BSX · basing · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 13.5% · Profit 46.7% · Operating margin change 4.3 points · 83% evidence Capital efficiency 16.3/25 · ROCE 11.4% · Operating margin 22.9% · 76% evidence Valuation 15.6/20 · P/E 17.3× · PEG 0.37 · 65% evidence Relative strength 4.3/20 · Lead over its industry -40.1% · Lead over S&P 500 -33.4% · 1 year -54.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25 + 16.3 + 15.6 + 4.3 = 61.2 · What this means: Earnings are strong; relative strength in its sector is -40.1% and the one-year return is -54.2%. 4. [Haemonetics Corporation](https://www.sectoralpha.in/us/stocks/hae) HAE · leader · Evidence leans up · 81% evidence 59.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.8/35 · Revenue 0.3% · Profit -40.5% · Operating margin change 0 points · 83% evidence Capital efficiency 15.3/25 · ROCE 11.8% · Operating margin 17.9% · 76% evidence Valuation 13.3/20 · P/E 36.5× · PEG 0.49 · 65% evidence Relative strength 19.6/20 · Lead over its industry 34.9% · Lead over S&P 500 50.5% · 1 year 86.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 10.8 + 15.3 + 13.3 + 19.6 = 59 · What this means: Relative strength against the index is 50.5%, and revenue and profit growth are weak. 5. [Insulet Corporation](https://www.sectoralpha.in/us/stocks/podd) PODD · turning · Evidence leans up · 71% evidence 58.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 29.4% · Profit 58.6% · Operating margin change -2.5 points · 83% evidence Capital efficiency 18.9/25 · ROCE 21.3% · Operating margin 16.2% · 76% evidence Valuation 9.3/20 · P/E 28.1× · PEG n/a · 15% evidence Relative strength 6.6/20 · Lead over its industry -31.6% · Lead over S&P 500 -24% · 1 year -48.4% · 100% evidence · 1 of 12 weeks ahead Exact sum: 23.8 + 18.9 + 9.3 + 6.6 = 58.6 · What this means: Earnings are strong; relative strength in its sector is -31.6% and the one-year return is -48.4%. 6. [Stryker Corporation](https://www.sectoralpha.in/us/stocks/syk) SYK · turning · Evidence leans up · 81% evidence 58.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 8.5% · Profit 27.8% · Operating margin change 5 points · 83% evidence Capital efficiency 18.8/25 · ROCE 14.9% · Operating margin 27% · 76% evidence Valuation 11.0/20 · P/E 32.4× · PEG 1.16 · 65% evidence Relative strength 6.0/20 · Lead over its industry -14.2% · Lead over S&P 500 -4% · 1 year -4.6% · 100% evidence · 1 of 12 weeks ahead Exact sum: 22.6 + 18.8 + 11 + 6 = 58.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Glaukos Corporation](https://www.sectoralpha.in/us/stocks/gkos) GKOS · leader · Evidence leans up · 64% evidence 56.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.2/35 · Revenue 41.8% · Profit n/a · Operating margin change 9.8 points · 62% evidence Capital efficiency 3.9/25 · ROCE -9.7% · Operating margin -8.5% · 76% evidence Valuation 11.2/20 · P/E -98.1× · PEG n/a · 15% evidence Relative strength 19.5/20 · Lead over its industry 51.3% · Lead over S&P 500 69.3% · 1 year 194.2% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22.2 + 3.9 + 11.2 + 19.5 = 56.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [STERIS plc](https://www.sectoralpha.in/us/stocks/ste) STE · turning · Evidence leans up · 81% evidence 55.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 8.3% · Profit 24.7% · Operating margin change 1.4 points · 83% evidence Capital efficiency 15.4/25 · ROCE 12.2% · Operating margin 19.2% · 76% evidence Valuation 12.5/20 · P/E 25.5× · PEG 1 · 65% evidence Relative strength 8.0/20 · Lead over its industry -10.4% · Lead over S&P 500 0.1% · 1 year -6% · 100% evidence · 4 of 12 weeks ahead Exact sum: 19.7 + 15.4 + 12.5 + 8 = 55.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. Medtronic plc this page MDT · breaking out · Evidence leans up · 85% evidence 55.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.1/35 · Revenue 9.8% · Profit 12.3% · Operating margin change 0.6 points · 95% evidence Capital efficiency 14.3/25 · ROCE 9.4% · Operating margin 19.3% · 76% evidence Valuation 9.3/20 · P/E 20.9× · PEG 1.72 · 65% evidence Relative strength 12.4/20 · Lead over its industry -2.8% · Lead over S&P 500 8.5% · 1 year 13.9% · 100% evidence · 9 of 12 weeks ahead Exact sum: 19.1 + 14.3 + 9.3 + 12.4 = 55.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [CONMED Corporation](https://www.sectoralpha.in/us/stocks/cnmd) CNMD · turning · Evidence leans up · 81% evidence 54.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.5/35 · Revenue 3.4% · Profit -48.2% · Operating margin change 3.2 points · 83% evidence Capital efficiency 11.5/25 · ROCE 8% · Operating margin 14.6% · 76% evidence Valuation 12.0/20 · P/E 17.4× · PEG 1.18 · 65% evidence Relative strength 16.5/20 · Lead over its industry 8.5% · Lead over S&P 500 21.2% · 1 year 22% · 100% evidence · 11 of 12 weeks ahead Exact sum: 14.5 + 11.5 + 12 + 16.5 = 54.5 · What this means: Relative strength against the index is 21.2%, and revenue and profit growth are weak. 11. [Koninklijke Philips N.V.](https://www.sectoralpha.in/us/stocks/phg) PHG · turning · Evidence leans up · 71% evidence 53.5 out of 100 Growth Capital Valuation Relative
12. [LivaNova PLC](https://www.sectoralpha.in/us/stocks/livn) LIVN · turning · Evidence leans up · 64% evidence 53.0 out of 100 Growth Capital Valuation Relative
13. [Edwards Lifesciences Corporation](https://www.sectoralpha.in/us/stocks/ew) EW · turning · Evidence leans up · 81% evidence 51.7 out of 100 Growth Capital Valuation Relative
14. [UFP Technologies, Inc.](https://www.sectoralpha.in/us/stocks/ufpt) UFPT · leader · Evidence leans up · 81% evidence 50.6 out of 100 Growth Capital Valuation Relative
15. [Zimmer Biomet Holdings, Inc.](https://www.sectoralpha.in/us/stocks/zbh) ZBH · turning · Evidence leans up · 81% evidence 50.0 out of 100 Growth Capital Valuation Relative
16. [iRhythm Holdings, Inc.](https://www.sectoralpha.in/us/stocks/irtc) IRTC · turning · Evidence leans down · 64% evidence 48.4 out of 100 Growth Capital Valuation Relative
17. [Integer Holdings Corporation](https://www.sectoralpha.in/us/stocks/itgr) ITGR · losing its lead · Too little evidence to rank firmly · 56% evidence 48.3 out of 100 Growth Capital Valuation Relative
18. [Smith & Nephew plc](https://www.sectoralpha.in/us/stocks/snn) SNN · turning · Too little evidence to rank firmly · 51% evidence 48.1 out of 100 Growth Capital Valuation Relative
19. [Bruker Corporation](https://www.sectoralpha.in/us/stocks/brkr) BRKR · turning · Evidence leans down · 71% evidence 47.7 out of 100 Growth Capital Valuation Relative
20. [Butterfly Network, Inc.](https://www.sectoralpha.in/us/stocks/bfly) BFLY · quiet · Evidence leans down · 61% evidence 47.7 out of 100 Growth Capital Valuation Relative
21. [GE HealthCare Technologies Inc.](https://www.sectoralpha.in/us/stocks/gehc) GEHC · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
22. [Neogen Corporation](https://www.sectoralpha.in/us/stocks/neog) NEOG · turning · Evidence leans down · 67% evidence 43.4 out of 100 Growth Capital Valuation Relative
23. [Axogen, Inc.](https://www.sectoralpha.in/us/stocks/axgn) AXGN · turning · Evidence leans down · 64% evidence 42.3 out of 100 Growth Capital Valuation Relative
24. [Establishment Labs Holdings Inc.](https://www.sectoralpha.in/us/stocks/esta) ESTA · basing · Evidence leans down · 61% evidence 40.7 out of 100 Growth Capital Valuation Relative
25. [Inspire Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/insp) INSP · breaking out · Evidence leans down · 74% evidence 39.7 out of 100 Growth Capital Valuation Relative
26. [NovoCure Limited](https://www.sectoralpha.in/us/stocks/nvcr) NVCR · quiet · Evidence leans down · 61% evidence 38.4 out of 100 Growth Capital Valuation Relative
27. [Bio-Rad Laboratories, Inc.](https://www.sectoralpha.in/us/stocks/bio) BIO · leader · Evidence leans down · 71% evidence 38.1 out of 100 Growth Capital Valuation Relative
28. [TransMedics Group, Inc.](https://www.sectoralpha.in/us/stocks/tmdx) TMDX · quiet · Evidence leans down · 71% evidence 36.3 out of 100 Growth Capital Valuation Relative
29. [Abbott Laboratories](https://www.sectoralpha.in/us/stocks/abt) ABT · turning · Most evidence points down · 85% evidence 34.5 out of 100 Growth Capital Valuation Relative
30. [Penumbra, Inc.](https://www.sectoralpha.in/us/stocks/pen) PEN · turning · Most evidence points down · 81% evidence 32.9 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Devices](https://www.sectoralpha.in/us/sectors/medical-devices), all 30 compared on one page. ## Which companies are close to Medtronic in size? Medtronic is the 3rd largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Abbott Laboratories and Stryker Corporation. Just below it: Boston Scientific Corporation, Edwards Lifesciences Corporation, GE HealthCare Technologies Inc. and DexCom, Inc. ### Medical Devices companies close in size

1. [Abbott Laboratories](https://www.sectoralpha.in/us/stocks/abt) $199.9 billion
2. [Stryker Corporation](https://www.sectoralpha.in/us/stocks/syk) $129.4 billion
3. Medtronic plc $128.6 billion
4. [Boston Scientific Corporation](https://www.sectoralpha.in/us/stocks/bsx) $66.4 billion
5. [Edwards Lifesciences Corporation](https://www.sectoralpha.in/us/stocks/ew) $57.3 billion
6. [GE HealthCare Technologies Inc.](https://www.sectoralpha.in/us/stocks/gehc) $38.8 billion
7. [DexCom, Inc.](https://www.sectoralpha.in/us/stocks/dxcm) $33 billion

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Spotify Technology S.A.](https://www.sectoralpha.in/us/stocks/spot) $129 billion · Internet Content & Information
2. [Lowe's Companies, Inc.](https://www.sectoralpha.in/us/stocks/low) $128.8 billion · Home Improvement Retail
3. Medtronic plc $128.6 billion
4. [Booking Holdings Inc.](https://www.sectoralpha.in/us/stocks/bkng) $128.4 billion · Travel Services
5. [Seagate Technology Holdings plc](https://www.sectoralpha.in/us/stocks/stx) $127.8 billion · Computer Hardware

## What else do people ask about Medtronic? ### What were Medtronic's latest quarterly results? Medtronic plc reported revenue of $9.8 B and net profit of $1.5 B for the Jul 2026 quarter. Revenue rose 13.7% and profit rose 41.3% compared with a year earlier. Earnings per share were $1.14. The operating margin was 19.3%, 0.6 percentage points higher than a year earlier (as of 4 November 2026). ### What is Medtronic's market cap? Medtronic plc's market capitalisation is $129 B at a stock price of $105.04. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Medtronic performing? Medtronic plc's share price has been stalling near its high for 5 weeks. In its latest quarter, revenue rose 13.7% and profit rose 41.3% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 15 weeks running (as of 4 November 2026). ### Will Medtronic's stock price go up? This page does not forecast Medtronic plc's stock price. What it shows instead: the stock price is $105.04, and it has been stalling near its high for 5 weeks. Its P/E of 25.9× is higher than 46% of its own last 5 years (as of 4 November 2026). ### Where is Medtronic in its business cycle? Medtronic plc's FY26 operating margin was 20.0%, against a 5-year range of 17.8% to 21.6%: the middle of its own range, neither a peak nor a low. The latest quarter was 19.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Medtronic story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Medtronic a stock worth studying right now? What the numbers show: Medtronic plc's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ## Lists

- S&P 500 companies: https://www.sectoralpha.in/sp-500-stocks

This is research, not advice. We’re not SEBI-registered.